Bradford White to showcase compact and efficient home heating solutions at Eastern Energy Expo
Trusted manufacturer to highlight Brute FT® Floor Boilers at premier energy industry event
AMBLER, Pa., May 15, 2025 /PRNewswire/ -- Bradford White Water Heaters, an industry-leading manufacturer of water heaters, boilers and storage tanks, will showcase a slate of compact and energy-efficient solutions at this year's Eastern Energy Expo, a flagship event for professionals in the home energy and comfort industry.
This year's tradeshow will take place May 20-21 at the Atlantic City Convention Center in Atlantic City, New Jersey.
"The home heating industry is evolving at a rapid pace, and we're proud to be working at the forefront to address demands for greater efficiency—all while maintaining the reliability we're known for," said Neal Heymen, senior director of marketing for Bradford White. "Tradeshows like this one provide a fantastic opportunity to demonstrate the value we're offering to our customers."
Representatives from Bradford White will be on site at booth #808 to highlight the company's robust product portfolio, with a focus on the Brute FT Floor Boiler. Features of the Brute include:
ENERGY STAR® certification, with peak-level efficiency to help homeowners keep their utility bills in check.
A space-saving design, making it an ideal option for areas where a smaller footprint is required.
Durable stainless-steel design, intended to provide years of reliable performance.
Eastern Energy Expo is an annual convention for wholesale and retail liquid fuel marketers, motor fuel distributors, diesel and biodiesel distributors, propane marketers and HVAC service professionals, offering both technical education opportunities as well as networking events. To learn more, visit www.easternenergyexpo.com.
For more information about Bradford White Water Heaters, visit www.bradfordwhite.com.
About Bradford White CorporationBradford White Corporation is a full-line manufacturer of residential, commercial, and industrial water heating, space heating, combination heating and storage products. The company maintains corporate headquarters in Ambler, PA, and has manufacturing facilities in Middleville and Niles, MI; Monticello, MN; Uxbridge, MA; Rochester, NH; and Princeton and Madison, WI. FloLogic's assembly operation is in Morrisville, NC and Bradford White Corporation's Canadian headquarters, distribution center and training facilities are in Halton Hills, Ontario, Canada. For more information, visit www.bradfordwhitecorporation.com.
BRADFORD WHITE CONTACT: Julia KleinSenior Marketing SpecialistBradford White Corporation(215) 641-9400jklein@bradfordwhite.com
MEDIA CONTACT:Heather RipleyRipley PR(865) 977-1973hripley@ripleypr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bradford-white-to-showcase-compact-and-efficient-home-heating-solutions-at-eastern-energy-expo-302454748.html
SOURCE Bradford White Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
La Jolla Cosmetic Medical Spa Opens Third Location in Temecula on June 2nd
San Diego's Most Trusted Med Spa Expands to the Inland Empire with Award-Winning Aesthetic Services TEMECULA, Calif., June 5, 2025 /PRNewswire/ -- La Jolla Cosmetic Medical Spa (LJC), a leader in aesthetic care for over three decades, is proud to announce the opening of its third medical spa location in Temecula, California, which opened on Monday, June 2, 2025. This new location brings LJC's award-winning services to the heart of the Temecula Valley. Founded in 1988, the La Jolla Cosmetic brand has been a staple of San Diego's aesthetic community for 35+ years. With medical spa locations in La Jolla and Carlsbad, the practice has earned recognition as an 8-time winner of "Best of San Diego" and is currently named a Top 10 Allergan provider in the nation for injectables like BOTOX® and JUVÉDERM®. Now expanding into Riverside County, LJC continues its mission to make world-class aesthetic care more accessible across Southern California. "Opening in Temecula marks a major milestone in our mission to provide personalized, natural results and build long-term relationships with our patients across Southern California," said Lauren Amico Reed, PA-C, MMS, Co-founder of La Jolla Cosmetic Medical Spa. "We are thrilled to bring our team's expertise and renowned aesthetic care to this incredible community." The Temecula location will offer the full range of LJC's most popular non-surgical services, including: Injectables: BOTOX®, JUVÉDERM®, Sculptra®, and more Skin Rejuvenation: HALO® laser, BBL Hero®, threads, microneedling, and medical-grade facials Hair & Wellness Treatments: Regenerative treatments for hair thinning and sexual wellness injectables Patients can expect the same elevated experience that has made LJC a trusted name in aesthetics—from highly trained providers to personalized treatment plans, all in a welcoming, luxurious setting. With this new location, the brand strengthens its vision of blending clinical excellence with deep community connection. Appointments for the Temecula location can be booked at or by calling (858) 228-4542. To celebrate the launch, LJC is offering an exclusive pre-sale special: 40 units of BOTOX® for $299 for a limited time. Additionally, the official grand opening celebration will be held on Saturday, July 19, from 12 p.m. to 3 p.m. Guests can enjoy: Exciting giveaways Exclusive swag bags for the first arrivals Live treatment demos Light bites and refreshments Fun activities and a chance to tour the new space RSVP: La Jolla Cosmetic Medical Spa – Temecula Grand Opening Event! About La Jolla Cosmetic Medical SpaLa Jolla Cosmetic Medical Spa (LJC) has been helping patients look and feel their best since 2013. Known for delivering natural-looking results through expert providers, advanced technology, and personalized care, LJC sets the standard for aesthetic excellence. With medical spa locations in La Jolla, Carlsbad, and now Temecula, LJC continues to set the standard for aesthetic care in Southern California. View original content to download multimedia: SOURCE La Jolla Cosmetic Medical Spa Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Global Antidote Market to Cross the USD 4 Billion Mark by 2032
The antidote market is witnessing substantial growth, largely propelled by the growing incidence of poisoning, drug overdoses, and snake or animal bites. This rising demand is supported by greater public health awareness, government efforts to combat drug overdoses, and continuous progress in product innovation. Moreover, strategic product launches and technological advancements by key industry players in the treatment of toxicities are further accelerating the market's upward momentum. New York, USA, June 05, 2025 (GLOBE NEWSWIRE) -- Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight The antidote market is witnessing substantial growth, largely propelled by the growing incidence of poisoning, drug overdoses, and snake or animal bites. This rising demand is supported by greater public health awareness, government efforts to combat drug overdoses, and continuous progress in product innovation. Moreover, strategic product launches and technological advancements by key industry players in the treatment of toxicities are further accelerating the market's upward momentum. DelveInsight's Antidote Market Insights report provides the current and forecast market analysis, individual leading antidote companies' market shares, challenges, antidote market drivers, barriers, trends, and key market antidote companies in the market. Key Takeaways from the Antidote Market Report As per DelveInsight estimates, North America is anticipated to dominate the global antidote market during the forecast period. In the antidote type segment of the antidote market, the biological antidotes category accounted for the largest market share in 2024. Notable antidote companies such as Pfizer Inc., SERB Pharmaceuticals, McKesson Corporation, Amneal Pharmaceuticals LLC, EMERGENT, Novartis AG, Troikaa, Hope Pharmaceuticals, Rare Disease Therapeutics, Inc., BTG International Inc., Viatris Inc., Glentham® Life Sciences Limited, Kaleo, Inc., SGPharma Pvt. Ltd., American Regent, Inc., FFF Enterprises, Inc., Amphastar Pharmaceuticals, Inc., Purdue Pharma L.P., Indivior PLC, Harm Reduction Therapeutics, Inc., and several others are currently operating in the antidote market. In August 2024, Purdue Pharma L.P. received FDA approval for the New Drug Application (NDA) of Zurnai™ (nalmefene injection) auto-injector. In March 2024, Indivior PLC announced the results of a pharmacodynamic study showcasing that OPVEE® effectively and rapidly reverses opioid-induced respiratory depression, the primary cause of death in opioid overdoses. This breakthrough demonstrates the potential of OPVEE® as a critical intervention in emergency overdose situations, offering a swift response to prevent life-threatening complications associated with opioid toxicity. To read more about the latest highlights related to the antidote market, get a snapshot of the key highlights entailed in the Global Antidote Market Report Antidote Overview Antidote refers to a substance that counteracts the harmful effects of a poison or toxin. When an individual is exposed to a toxic substance, whether through ingestion, inhalation, injection, or skin contact, an antidote can help neutralize the toxin, reverse its effects, or support the body's natural elimination processes. Antidotes work through various mechanisms: some bind directly to the toxin, others block its biological effects, and some enhance the body's own detoxification systems. Common examples include activated charcoal for many oral poisons, naloxone for opioid overdoses, and atropine for certain nerve agent or pesticide exposures. The development and timely administration of antidotes are crucial in emergency medicine and toxicology. While some antidotes are broadly effective against a wide range of toxins, others are highly specific, targeting a single compound or class of poisons. Due to the diversity of toxic agents and the complexity of their effects on human biology, ongoing research in pharmacology and biochemistry continues to play a critical role in discovering new antidotes. In mass exposure events or cases of rare poisoning, the availability and distribution of appropriate antidotes can be a matter of life and death, underscoring their significance in public health preparedness and clinical Market Insights North America held a substantial share of the antidote market in 2024, fueled by several critical factors. The growing number of poisoning and drug overdose incidents across the region has significantly increased the need for effective antidote solutions. In particular, the opioid epidemic in the United States has driven demand for treatments like naloxone, which can reverse opioid overdoses. Public health campaigns and government-led efforts to curb and manage drug overdoses have further enhanced access to antidotes. Moreover, the market is witnessing a boost from ongoing pharmaceutical innovation and the introduction of new, targeted treatments. In response to this concerning trend, regional authorities have launched various initiatives to address drug overdoses and poisoning. For example, the U.S. Food and Drug Administration (FDA) implemented the Overdose Prevention Framework, which aims to reduce unnecessary opioid prescriptions, encourage harm-reduction strategies through education and innovation, and support the development of evidence-based therapies for substance use disorders and overdoses. Canada is also actively combating the overdose crisis. The Canadian government is investing in prevention programs, expanding access to treatment and harm-reduction services, and leveraging data-driven approaches to guide policy-making. These comprehensive efforts are fostering an environment conducive to the growth of the antidote market across North America. Additionally, pharmaceutical companies in the region are intensifying research and development efforts to bring advanced overdose treatments to market. For instance, in August 2024, Purdue Pharma L.P. received FDA approval for its New Drug Application (NDA) for Zurnai™ (nalmefene injection) auto-injector. This product is designed for emergency use in opioid overdoses caused by both natural and synthetic opioids in adults and adolescents aged 12 and above. The approval of Zurnai™ has expanded the arsenal of available opioid overdose antidotes, offering a fast-acting, user-friendly option to help tackle the ongoing opioid crisis. To know more about why North America is leading the market growth in the antidote market, get a snapshot of the Antidote Market Outlook Antidote Market Dynamics The antidote market is a crucial segment of the global pharmaceutical and toxicology landscape, driven by the increasing incidence of poisoning cases from pharmaceuticals, snake bites, chemical exposure, and overdoses. With growing awareness about drug misuse and rising environmental hazards, the demand for antidotes has surged in both developed and developing countries. Additionally, the rise in hospital admissions due to opioid overdoses, especially in North America and parts of Europe, has directly increased the need for effective and rapid-response antidotes like naloxone. One of the primary market dynamics shaping the antidote sector is the regulatory landscape. Antidotes, often falling under emergency-use drugs, receive fast-track approvals in certain jurisdictions due to their life-saving potential. Governments and healthcare bodies have also begun stockpiling critical antidotes as part of national preparedness programs, especially in regions vulnerable to snake bites or chemical attacks. Furthermore, innovations in biotechnology have allowed the development of more targeted and efficient antidotes, including monoclonal antibodies and small molecule inhibitors tailored for specific toxins or venoms. However, the market faces significant challenges. Many antidotes are expensive to develop and maintain, especially when the target population is small or geographically limited. For example, antivenoms for rare snake species may not be commercially viable due to high R&D costs and limited demand. This has led to a reliance on public-private partnerships and NGO involvement to ensure production and distribution in low-income areas. Moreover, the shelf-life and storage requirements of many antidotes add to supply chain complexity, often limiting their availability in remote or underdeveloped regions. Looking ahead, the antidote market is expected to benefit from increased global focus on public health preparedness and bioterrorism defense. The COVID-19 pandemic underscored the importance of rapid medical response capabilities, prompting governments to revisit their emergency drug inventories. Additionally, as pharmaceutical companies invest in advanced drug delivery systems and synthetic biology, novel antidotes with longer shelf lives and broader efficacy profiles are likely to emerge. The integration of digital health tools and AI in toxicology response systems could also streamline the identification and administration of antidotes, improving patient outcomes and operational efficiency in emergency care. Get a sneak peek at the antidote market dynamics @ Antidote Market Trends Report Metrics Details Coverage Global Study Period 2022–2032 Antidote Market CAGR ~7% Antidote Market Size by 2032 USD 4 Billion Key Antidote Companies Pfizer Inc., SERB Pharmaceuticals, McKesson Corporation, Amneal Pharmaceuticals LLC, EMERGENT, Novartis AG, Troikaa, Hope Pharmaceuticals, Rare Disease Therapeutics, Inc., BTG International Inc., Viatris Inc., Glentham® Life Sciences Limited, Kaleo, Inc., SGPharma Pvt. Ltd., American Regent, Inc., FFF Enterprises, Inc., Amphastar Pharmaceuticals, Inc., Purdue Pharma L.P., Indivior PLC, Harm Reduction Therapeutics, Inc., among others Antidote Market Assessment Antidote Market Segmentation Antidote Market Segmentation By Type: Chemical Antidotes and Biological Antidotes Antidote Market Segmentation By Route of Administration: Oral and Parenteral Antidote Market Segmentation By Distribution Channel: Hospital and Retail Pharmacies Antidote Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the antidote market are set to emerge as the trendsetter explore @ Antidote Companies Table of Contents 1 Antidote Market Report Introduction 2 Antidote Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Antidote Market Key Factors Analysis 6 Antidote Market Porter's Five Forces Analysis 7 Antidote Market Layout 8 Antidote Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the antidote market by 2032? Click to get a snapshot of the Antidote Market Analysis Related Reports Heavy Metal Poisoning Market Heavy Metal Poisoning Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key heavy metal poisoning companies, including EmeraMed, Magellan Diagnostics, Bezoloven Inc., among others. Substance Use Disorder Market Substance Use Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SUD companies including BioXcel Therapeutics, NFL Biosciences, STALICLA, Embera NeuroTherapeutics, PleoPharma, Kinnov Therapeutics, Imbrium Therapeutics, Atai Life Sciences, Beckley Psytech, among others. Opioid Use Disorder Market Opioid Use Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key OUD companies including Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, Camurus, among others. Cocaine Use Disorder Market Cocaine Use Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CUD companies including STALICLA, Embera NeuroTherapeutics, among others. Cocaine Intoxication Market Cocaine Intoxication Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cocaine intoxication companies including Tonix Pharmaceutical, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us Shruti Thakur info@ +14699457679Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology
PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ('Treace' or the 'Company') (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® procedures, today announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, 'Zimmer') (NYSE: ZBH), alleging infringement of 4 patents related to Treace's innovative Lapiplasty® 3D Bunion Correction® technologies. The suit was filed in the United States District Court for the District of Delaware, and seeks injunctive relief and damages. 'Treace Medical was the first company to develop, patent, and introduce an instrumented 3D bunion correction system for true tri-planar lapidus bunion correction and is the recognized leader in the surgical treatment of bunions. We believe that this lawsuit is necessary to protect the significant investments we have made in our pioneering research and technology, which is in the best interest of our stockholders,' said John T. Treace, Chairman, CEO and Founder of Treace. 'Enforcing and defending our intellectual property helps to drive our ability to continue to innovate solutions that benefit patients.' Treace's patent portfolio includes 80 granted U.S. patents, with an additional 26 granted patents worldwide and over 150 pending patent applications. About Treace Medical Concepts Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram. Contacts:Treace Medical ConceptsMark L. HairChief Financial Officermhair@ 373-5940 Investors:Gilmartin GroupPhilip Trip Taylor IR@
